Norastemizole non-sedating antihistamine data

SEPR announced Phase II results in 381 patients, showing statistically significant improvement at the two higher doses tested. Norastemizole is a metabolite of Johnson & Johnson's Hismanal astemizole antihistamine. Allergic symptoms such as rhinorrhea, sneezing, itchy eyes and nose, and scratchy throat were improved compared to placebo. No difference in side effects was seen compared to placebo, including cardiac events measured by ECG.

Doses of 5, 20, or 62.5 mg were given for consecutive two days. The tests took place in two parks in the Midwest, with patients exposed to spring pollen. Self-rating of symptoms showed a decrease in scores, with 40 percent reduction at one hour and 60 percent reduction at five hours. Statistical significance was achieved by 22 hours and was sustained all the following day. ...